Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 44 Prostatic Neoplasms, Castration-Resistant 2 Neoplasm Metastasis 2 Stage II Prostate Adenocarcinoma 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Prostate Cancer Metastatic Disease 1 Prostate Adenocarcinoma 1 Newly Diagnosed Oligometastatic Prostate Cancer 1 Neoplasms 1 Neoadjuvant Therapy 1 Low Risk Prostate Cancer 1 High Risk Prostate Cancer 1 Hematologic Neoplasms 1 Castration Levels of Testosterone 1 Carcinoma, Small Cell 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cyclophosphamide 41 fludarabine 35 Tacrolimus 28 Mycophenolic Acid 27 Whole-Body Irradiation 25 Busulfan 24 fludarabine phosphate 21 Melphalan 19 thymoglobulin 16 Antilymphocyte Serum 16 Methotrexate 13 Thiotepa 12 Stem Cell Transplantation 9 Rituximab 9 Granulocyte Colony-Stimulating Factor 9 Filgrastim 8 Cyclosporine 8 trametinib 7 Sirolimus 7 Nivolumab 5 ruxolitinib 4 merphos 4 Peripheral Blood Stem Cell Transplantation 4 Cytarabine 4 Cord Blood Stem Cell Transplantation 4 Bendamustine Hydrochloride 4 tocilizumab 3 itacitinib 3 fedratinib 3 dabrafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hematologic Neoplasms × apalutamide × Clear all

NCT05159245 2024-07-15

FINPROVE

Helsinki University Central Hospital

Phase 2 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡